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Abstract
Background: Cervical carcinoma develops as a result of multiple genetic alterations. Different studies
investigated genomic alterations in cervical cancer mainly by means of metaphase comparative genomic
hybridization (mCGH) and microsatellite marker analysis for the detection of loss of heterozygosity
(LOH). Currently, high throughput methods such as array comparative genomic hybridization (array
CGH), single nucleotide polymorphism array (SNP array) and gene expression arrays are available to study
genome-wide alterations. Integration of these 3 platforms allows detection of genomic alterations at high
resolution and investigation of an association between copy number changes and expression.
Results: Genome-wide copy number and genotype analysis of 10 cervical cancer cell lines by array CGH
and SNP array showed highly complex large-scale alterations. A comparison between array CGH and SNP
array revealed that the overall concordance in detection of the same areas with copy number alterations
(CNA) was above 90%. The use of SNP arrays demonstrated that about 75% of LOH events would not
have been found by methods which screen for copy number changes, such as array CGH, since these were
LOH events without CNA. Regions frequently targeted by CNA, as determined by array CGH, such as
amplification of 5p and 20q, and loss of 8p were confirmed by fluorescent in situ hybridization (FISH).
Genome-wide, we did not find a correlation between copy-number and gene expression. At chromosome
arm 5p however, 22% of the genes were significantly upregulated in cell lines with amplifications as
compared to cell lines without amplifications, as measured by gene expression arrays. For 3 genes, SKP2,
ANKH and TRIO, expression differences were confirmed by quantitative real-time PCR (qRT-PCR).
Conclusion: This study showed that copy number data retrieved from either array CGH or SNP array
are comparable and that the integration of genome-wide LOH, copy number and gene expression is useful
for the identification of gene specific targets that could be relevant for the development and progression
in cervical cancer.
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Background
The development of cervical cancer is a multi-step process.
This process starts with infection of the epithelial layer
with high-risk human papilloma virus (HPV). Cervical
intraepithelial neoplasia (CIN) grade I, II and III, repre-
senting reversible stages of disease, is believed to develop
towards neoplasm. From CIN I onwards genomic altera-
tions and aneuploidy can be detected [1,2] and when dis-
ease is progressing towards CIN II and III, genetic
alterations become more evident [3]. HPV E6 and E7 can
induce cellular transformation due to interaction with cel-
lular proteins involved in cell cycle control, apoptosis and
genomic instability [4]. The induction of genomic insta-
bility seems to be particularly important for the establish-
ment and development of an invasive tumour [5].
So far, different studies have investigated genomic altera-
tions in cervical cancer by means of metaphase compara-
tive genomic hybridization (mCGH) and microsatellite
marker analysis for the detection of loss of heterozygosity
(LOH). Chromosomal changes involving loss of 2q, 3p,
4p, 4q, 5q, 6q, 11q, 13q and 18q regions and gain of 1q,
3q, 5p and 8q regions at various stages of disease have
been identified [1,6-8]. Some of these imbalances have
been associated with decreased survival such as LOH of
18q [9] or with the transition from severe dysplasia to
invasive carcinoma such as gain of 3q [10]. However, few
genes, targeted by these genomic imbalances and possibly
involved in carcinogenesis, have been discovered due to
the lack of resolution when applying mCGH [11] whereas
classical LOH studies are laborious. Array comparative
genomic hybridization (array CGH) is an established high
resolution method to study the whole genome for chro-
mosomal amplifications and deletions [12]. Although
array CGH has relatively few printed elements on the
arrays, the strength of this technique is the high spatial
resolution [13]. A limitation of array CGH is the lack of
genotype information. Therefore, it does not provide
information about regions of LOH without copy number
alteration (CNA) such as mitotic recombination or gene
conversion events. The under-reprepresentation of LOH
in copy number methods may be very high with up to 2/
3 of LOH events being undetected because of copy-neutral
and copy-gain LOH events, as was found in pancreatic
cancer [14]. Recently, high-density oligonucleotide-based
single polymorphism arrays (SNP arrays) have been used
to identify copy number and LOH of chromosomal
regions [15,16]. Appropriate software tools for the detec-
tion of CNA from SNP data are becoming available. The
advantage of a combined SNP-CGH approach is the iden-
tification of allele specific gain and loss by SNP array and
the robust copy number detection by array CGH.
Different factors, including changes in genome copy
number, can disrupt proper gene functioning. A few stud-
ies showed correlations between chromosome CNA and
gene expression changes of the affected regions [17,18]. In
this study, genome-wide LOH and copy number analyses
of 10 cervical cancer cell lines were investigated using SNP
and CGH arrays and the sensitivity to detect CNA by the 2
platforms was compared. We aimed at identifying com-
mon regions of gains and losses and determining the
influence of CNA on gene expression to find genes
involved in cervical carcinogenesis.
Results
Genome-wide LOH and copy number analyses of 10 cer-
vical cancer cell lines were investigated using SNP and
CGH arrays to identify common regions of amplification.
Also the two platforms were compared in their sensitivity
to detect CNA. Furthermore, data from gene expression
arrays were combined with array CGH data to investigate
an association between gene expression and copy
number.
CGH and SNP-LOH analysis
Various genomic alterations affecting the majority of
chromosomes were found in cervical cancer cell lines. The
CGH findings for all amplifications, gains and losses
detected in these cell lines are displayed in Figure 1A.
Gains or amplifications of 5p, 5q, 8q, 9q, 17q and 20q
occurred in most of the cell lines. Physical loss of chromo-
somal regions at 4p, 8p, 11q, 13q and 18q, occurred in at
least half of the cell lines. Regions frequently targeted by
gain or loss with small overlapping regions were present
at 8p, 8q, 9p, 11q and 17q. The minimal region of overlap
at 8p23 involved TUSC3, a tumor suppressor gene that
showed loss in 5 cell lines. At 8q24, the minimal region of
overlap included c-Myc which showed gain in 8 out of 10
cell lines. Amplification at 9q33-q34 included endoglin, a
gene involved in tumor angiogenesis and predictive for
metastasis in cervical cancer [19]. Loss at 11q25 involved
2 members of the IgLON family of cell adhesion mole-
cules, OPCML and HNT. The minimal region of overlap at
17q11-q21 included ERBB2 and TOP2A, genes that are
amplified in breast cancer [20]. As for SNP-LOH, most
chromosome arms were affected by LOH in the cell lines
(Figure 1B). More than 5 overlapping regions of LOH
were evident for chromosome region 5q, 6, 8p, 10q, 11q,
14q, 18 and 20p.
Comparison between SNP and BAC microarray
Concordance between array CGH and SNP array in the
detection of CNA was investigated. Overall, the BAC and
SNP arrays identified exactly the same regions of gain in
91% of cases, when taking an average of all cell lines
(Table 1). Similarly, the detection of the same regions
with loss between the 2 techniques was on average 94%
(Table 1). Subsequently, we investigated the overlap
between copy number loss and LOH and copy numberBMC Genomics 2007, 8:53 http://www.biomedcentral.com/1471-2164/8/53
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Chromosomal gains and losses in cervical cancer cell lines Figure 1
Chromosomal gains and losses in cervical cancer cell lines. A) Array CGH results are depicted by lines to the right of the chro-
mosomes as gains and on the left as losses. Thick solid lines represent regions with amplifications of more than 1 copy loss. B) 
SNP-LOH results show LOH as lines on the left side of the chromosomes. The letters above the lines indicate the cell lines: a) 
CSCC7, b) CSCC1, c) CC11-, d) CC11+, e) CaSki, f) CC8, g) CC10b, h) CC10a, i) SiHa and j) HeLa.BMC Genomics 2007, 8:53 http://www.biomedcentral.com/1471-2164/8/53
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gain and LOH for both platforms. For LOH to occur,
measured as a reduction in copy number, physical loss is
required. Thus all cases with copy number reductions are
expected to have undergone LOH. In case of physical loss,
around 60% was observed to encompass regions of LOH
(Table 2). Overall, copy number reductions as measured
by array CGH showed a higher overlap with LOH than
SNP array (Table 2), namely 66% for array CGH and 57%
for SNP array, when taking an average of all cell lines. The
occurrence of physical gain involves a change in copy
number and thus a change in the proportion of genotypes
which would imply a call for LOH. Around 28% of copy
number gain was found to cover regions of LOH (Table 2)
and frequencies were comparable between SNP array and
array CGH. Also, the overall percentage of LOH in copy
neutral, copy gain and copy loss events was investigated
for each cell line. The average frequency of LOH from all
cell lines was 21–26% for loss, 17% for gain and 60% for
copy neutral events (Table 3). Although array CGH and
SNP array are comparable in the level of detection of copy
number gain and loss, alterations in regions of LOH were
often not found by copy number analysis because these
LOH changes did not result in CNA (Figure 1 and Table
3). For example, 6 of 10 cell lines showed LOH of 6p
while array CGH detected physical loss of 6p in only one
cell line. This suggests that the other 5 cell lines underwent
mitotic recombination upon loss of one arm, thereby not
affecting copy number. Examples of complex genomic
alterations are shown for chromosome 8 and 20 of SiHa
and chromosome 3 of CaSki (Figure 2). In these examples
(Figure 2A and 2B), LOH is caused by loss of one chromo-
some, accompanied by duplication of the remaining chro-
mosome and subsequent deletions and translocations.
The copy number data from SNP array as deduced from
the dChip data (in blue lines) and array CGH (red lines)
clearly follow the same pattern in these examples, sup-
porting their compliance.
Correlation between DNA copy number and gene 
expression
To correlate the chromosomal changes to alterations in
gene expression profiles, we have searched for changes in
the expression of genes located in the regions targeted by
chromosomal gains and deletions. This was done by com-
bining gene expression data from Affymetrix focus arrays
with array CGH data. The average gene expression values
of all cell lines were used as a reference for each cell line
to determine increases or decreases in gene expression.
Genome-wide, no correlation was observed between
copy-number and expression. Since 5p, 8p23, 8q24,
9q33-q34, 11q25 and 20q are regions with many altera-
tions, we focused on these areas. For 20q we compared
cell lines harboring amplifications with cell lines contain-
ing gains since no cell line was devoid of 20q gain or
amplification but we did not find significant differences
in gene expression. Neither did we find significant
changes in gene expression at 8p23, 8q24 and 11q25. At
9q33-q34, cell lines with amplification (CSCC7, CC11+,
CC10A, CC10B, SiHa and HeLa) showed a significantly
higher expression compared to cell lines with gains or no
CNA correlation for 9 out of 86 genes (10%); POMT1,
FLJ35348,  LHX3,  NDOR,  SH3GLB2,  ST6GALNAC4,
CDK9, PTAN1 and TRAF2 (p < 0.05, T-test), of which the
latter 3 have been implicated in tumorigenesis. Fourteen
of 64 genes (22%) at 5p showed a significantly higher
expression in cell lines with amplification (CaSki, SiHa
and HeLa) compared to cell lines with gains or no CNA
(Table 4).
Validation of genetic alterations by FISH and LOH
The DNA copy number retrieved from the array CGHs was
validated by FISH. Based on the gained, amplified or lost
regions of 5p, 20q and 8p, BACs were selected that cov-
ered potential oncogenes or tumour suppressor genes.
FISH analysis on all cell lines was performed using the
BAC clones encompassing SKP2, TRIO, hTERT, GDNF and
ANKH  genes on 5p, TUSC3  on 8p and ZNF-217,
CYP24A1, MYBL2 and AIB1  on 20q (Table 5). Besides
additional copies of the area covered by BACs at 5p, other
complex genetic alterations such as translocations and
inversions were detected (Figure 3A). TUSC3 is a putative
tumour suppressor gene at 8p that is covered by 2 overlap-
ping BAC clones, RP11-44L18 and RP11-184C1 BAC.
Loss of the area at 8p was concordant between array CGH
and FISH for CC10A, CC11- and SiHa (Figure 3B). Signals
for BACs at chromosome 20q were equal to the number
of centromere signals or showed additional copies (Table
5 and Figure 3C), indicating that the whole arm or the
chromosome was gained, which is in agreement with the
array CGH data (Figure 1A). Overall, FISH assays con-
firmed the accuracy in which DNA CNA were detected by
array CGH for these loci and highlighted the gains and
amplifications of the ZNF-217,  CYP24A1,  MYBL2  and
AIB1 genes at 20q, SKP2, TRIO, hTERT, GDNF and ANKH
genes at 5p and the loss of the TUSC3 gene at 8p. LOH of
6p detected by SNP array in cell line CC11-, CC11+ and
CC10A was confirmed by LOH analysis of the tumors
from which the cell lines originate, using microsatellite
markers (Figure 4).
Validation of gene expression by qRT-PCR
To validate the microarray data, upregulated expression of
3 potential oncogenes (SKP2, ANKH and TRIO) were ana-
lyzed by qRT-PCR. These genes were located on 5p that
was shown to be gained or amplified by CGH in half of
the cell lines. Microarray data showed upregulation of
ANKH in 2 of the 3 cell lines with amplification of 5p
which did not reach statistical significance. Five normal
cervical epithelial cell cultures (NPE) were included in the
analysis to investigate the difference in expression levelBMC Genomics 2007, 8:53 http://www.biomedcentral.com/1471-2164/8/53
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between normal and tumour cells, with and without
amplification, from the cervix. Expression was signifi-
cantly different between cell lines with 5p amplification,
cell lines with 5p gains or no 5p alterations, and NPE (Fig-
ure 5). At chromosome arm 8p, deletion of the tumour
suppressor gene TUSC3, as found by FISH analysis (Table
5 and Figure 3B), was evident in CaSki, SiHa, CC10A,
CC11- and CC11+. No probe set on the expression array
was available for TUSC3. Therefore, qRT-PCR was carried
out on all cell lines. Only SiHa and CaSki showed a sub-
stantial drop in expression, compared to the expression
levels of the other cell lines and NPE (data not shown).
Discussion
The present study describes genome wide LOH and copy
number analyses of 10 cervical cancer cell lines using SNP
and CGH arrays to identify common regions of amplifica-
tion and deletion. Also, the sensitivity to detect CNA by
the 2 platforms was compared. Furthermore, integrated
copy number and gene expression analyses were per-
formed to investigate an association between CNA and
gene expression.
CNA retrieved from array CGH and genotype information
analyzed from SNP arrays revealed very complex large-
scale changes. Chromosome arms that were found to be
gained and/or amplified in most of the cell lines by array
CGH in this study were 5p, 8p, 8q, 9p, 9q, 17q and 20q.
Especially gains of 5p, 8q and 20q have been frequently
reported in cervical cancer [6,7,10,21-25]. Also the 1q and
3q arms, often found to be gained [7,10,21,24-26], were
overrepresented in 5 of the 10 cell lines. Gains of 17q and
chromosome 9 are less consistently reported [6,22]. Gain
of 8q24, present in 8 cell lines, included c-Myc in the min-
imal region of overlap. Amplification of the c-Myc onco-
gene is a frequent event in cervical tumors, found in 25%
Table 1: Percentage of gains and losses, determined for array CGH and SNP array data.
Gains Losses
Cell line SNP (%) CGH (%) Con. (%) SNP (%) CGH (%) Con. (%)
CSCC1 20.6 26.9 88.3 14.9 10.4 94.6
CSCC7 16.9 16.4 93.9 16.7 12.3 95.4
CC8 35.7 30.2 88.6 12.5 11.3 89.6
CC10A 10.3 23.5 86.9 19.7 8.2 83.4
CC10B 15.9 11.2 94.4 21.7 17.4 95.4
CC11- 16.4 13.9 92.9 2.4 1.8 99.3
CC11+ 11.0 14.5 93.9 3.5 1.8 98.3
CasKi 20.7 30.5 87.6 22.6 13.8 91.1
SiHa 12.6 13.7 92.7 23.1 20.9 94.1
HeLa 30.3 24.0 86.2 5.4 3.9 98.2
Average 19.0 20.5 90.5 14.3 10.2 93.9
The percentage of concordance between both techniques is shown in the latter column of gains and losses. Abbreviations: Con. is concordance.
Table 2: Percentage of overlap between LOH and copy number gains and losses.
% overlap between LOH and CNA
Gains Losses
Cell line SNP (%) CGH (%) SNP (%) CGH (%)
CSCC1 41.3 30.2 39.4 52.1
CSCC7 13.1 14.9 72.0 92.0
CC8 17.8 16.9 4.8 18.2
CC10A 26.6 15.7 73.9 82.2
CC10B 22.1 35.4 45.6 42.4
CC11- 32.3 38.9 77.3 90.1
CC11+ 9.1 6.9 57.2 87.5
CasKi 60.8 52.4 52.4 45.7
SiHa 38.1 49.6 95.7 97.0
HeLa 19.5 15.8 46.6 54.8
Average 28.1 27.7 56.5 66.2BMC Genomics 2007, 8:53 http://www.biomedcentral.com/1471-2164/8/53
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to more than half of the tumours [27,28]. Chromosome
arms affected by loss in half, or more, of the cell lines were
4p, 8p, 11q and 13q of which especially 4p and 13q have
been reported regularly in cervical cancer
[7,10,22,25,26,29]. Six cell lines showed loss of 11q25
that includes OPCML in the minimal region of overlap.
OPCML is a tumour suppressor gene in epithelial ovarian
cancer [30]. Although the genotype data have to be inter-
preted with some caution because of the use of cell lines,
many of the frequent changes that we observed were in
concordance with previous studies.
The SNP-LOH array data showed that most chromosome
arms were affected by LOH in the cell lines. More than 5
overlapping regions of LOH were evident for chromo-
some region 5q, 6p, 6q, 8p, 10q, 11q, 14q, 18p, 18q and
20p. LOH of the majority of these chromosomes, specifi-
cally 5q, 6p, 8p, 10q, 11q and 18, has been reported pre-
viously as frequent events in cervical cancer [9,31,32].
Whereas LOH of 8p resulted in copy number loss, LOH of
6p did not result in CNA for most cases, indicative of
mitotic recombination events.
A comparison between CGH and SNP array revealed that
the overall concordance in detection of the same areas
with CNA was on average 91% for gain and 94% for loss
(Table 1). Thus both platforms are comparable in the
detection of particular regions with gain or loss. Addition-
ally, the use of high-density SNP arrays showed that cervi-
cal cancer cell lines harbor multiple regions of LOH which
are not detected by methods which screen for CNA such
as array CGH. Accordingly, comparison of array CGH and
SNP array in genome-wide analysis shows that detection
of CNA by SNP array is reliable and has the added advan-
tage of providing genotype information. However, LOH
was not consistently detected by SNP array because many
copy number changes did not result in true reduction to
homozygosity since most of the cervical cancer cell lines
are multiploid (Figure 2C and Table 2). As expected, the
areas with gain and amplification showed less LOH than
regions with deletion. The overlap between copy-reduc-
tion regions and LOH was 10% higher for array CGH than
for SNP array (Table 2), which suggests that array CGH is
slightly better in assigning the correct regions for CNA.
Although some regions of LOH are missed, thereby partic-
ularly underestimating the amount of LOH in areas with
gain and amplification, an estimation was made for the
distribution of LOH in regions with loss, gain and copy-
neutral regions. We found that copy-neutral and copy-
gain regions accounted for around 75% of all LOH iden-
tified (17% represented copy-gain LOH) while LOH asso-
ciated with copy-reduction occurred at a rate of about
25% (Table 3). These percentages are similar to a recently
published paper from Calhoun et al. that described only
32% of LOH events to be associated with copy-reduction
[14]. Further improvement in the data from the SNP
arrays may be possible using higher density SNP arrays,
thereby increasing resolution and the ability to assess sub-
tle copy number changes.
Genome-wide, we did not find a correlation between
copy-number changes and expression. Lack of an associa-
tion may be due to the different histological types from
which the cell lines originate (Squamous carcinoma, Ade-
nocarcinomas and Adenosquamous carcinomas) with
complex genetic aberrations. Besides increased DNA dos-
age which may result in overexpression, transcription is
influenced by other factors such as the presence and quan-
tity of transcription and repressive factors; CpG methyla-
tion; histone methylation and acetylation status, and
possibly microRNA's [33]. Thus, amplification or deletion
on its own does not have to be a prerequisite for a change
Table 3: Percentage of LOH determined for copy neutral, copy gain and copy loss events.
% LOH
Copy neutral Gain Loss
Cell line SNP (%) CGH (%) SNP (%) CGH (%) SNP (%) CGH (%)
CSCC1 25.7 30.4 43.9 41.8 30.3 27.7
CSCC7 17.5 19.8 12.8 14.1 69.6 66.0
CC8 79.1 78.5 19.0 15.3 1.7 6.2
CC10A 62.7 77.6 5.9 7.9 31.3 14.4
CC10B 52.3 59.6 12.5 14.2 35.2 26.2
CC11- 80.1 80.7 14.7 14.9 5.2 4.4
CC11+ 83.6 86.1 5.5 5.5 10.9 8.4
CasKi 53.4 60.0 20.5 26.6 26.0 13.7
SiHa 54.6 54.2 8.1 11.5 34.3 37.3
HeLa 63.3 74.1 25.8 16.6 10.9 9.4
Average 57.2 62.1 16.9 16.8 25.5 21.4BMC Genomics 2007, 8:53 http://www.biomedcentral.com/1471-2164/8/53
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in gene expression. Amplification of 5p, however, corre-
lated with a significant higher gene expression for 22% of
the genes, including SKP2,  TRIO,  OSMR,  RPL37  and
PDCD6  (Table 4). The latter genes were previously
reported in cancer, either associated with increased
expression or with growth stimulatory properties [34-38].
Complex genomic alterations of chromosome 20 (A) and chromosome 8 (B) of SiHa and chromosome 3 of CaSki (C) Figure 2
Complex genomic alterations of chromosome 20 (A) and chromosome 8 (B) of SiHa and chromosome 3 of CaSki (C). Below 
each chromosome ideogram, SNP array data are shown in blue and array CGH data in red. The blue line directly beneath the 
ideogram depicts LOH, whereas the blue line shifting around the baseline (0) shows copy number retrieved from SNP array 
data. The dotted blue and red lines represent the confidence intervals for the copy number of the SNP and the CGH array, 
respectively.BMC Genomics 2007, 8:53 http://www.biomedcentral.com/1471-2164/8/53
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Array CGH findings of CNA at 5p, 8p and 20q were con-
firmed by FISH analysis. Gains and amplifications at 5p,
as found by array CGH, were validated by BACs covering
candidate oncogenes, SKP2,  TRIO,  ANKH,  GDNF  and
hTERT. SKP2 is important for cell cycle progression and its
inhibition decreases proliferation of tumour cells [39].
Besides gain of the region covering the SKP2 gene, we
found a significant increase in expression between normal
cervical epithelial cells, tumour cells without amplifica-
tion and tumour cells with amplification. Correlation
between amplification of chromosome 5p and increased
expression of SKP2 was previously shown in HPV-immor-
talized keratinocytes [40]. Upregulated expression of
SKP2, ANKH and TRIO, as determined by qRT-PCR in cell
lines with 5p amplification, confirmed gene expression
data from Affymetrix focus arrays. TRIO, which has a puta-
tive role in cell cycle regulation, was found to be amplified
and highly expressed in bladder cancer [35] that associ-
ated with proliferation and invasive phenotype. ANKH,
which is involved in tissue calcification [41], was found to
be amplified in bladder cancer [35] and small cell lung
cancer cell lines [42]. Thus, upregulation of expression
through amplification may be the case for TRIO, ANKH
and SKP2 in some neoplasms, including cervical cancer,
as indicated by our data. This may hold for hTERT and
PRKAA1 as well since it was reported that amplification at
5p in cervical cancer correlated with increased gene and/
or protein expression [43,44]. The telomeric region at 8p
includes a candidate tumour suppressor gene, TUSC3
[45,46]. However, physical loss of this region did not cor-
relate with a decrease in gene expression of TUSC3, as
determined by qRT-PCR. All cell lines showed gains or
amplifications of 20q, a chromosome arm which is often
amplified in cancer, including cervical cancer
[10,22,24,47]. At 20q increased copy numbers, detected
by array CGH, were confirmed by FISH. Candidate onco-
genes, ZNF-217, CYP24A1, MYBL2 and AIB2, encompass-
ing the region analyzed by FISH, were previously reported
to be amplified in other types of cancer as well [48-50].
However, no significant difference in gene expression was
found between tumours with gain and tumours with
amplification of 20q. Also in oesophageal adenocarci-
noma, no correlation was detected between amplification
Table 5: Aberrations determined by FISH analysis at chromosomes 5, 8 and 20.
Gene Location BAC clone 1 7 8 10a 10b 11- 11+ S C H
SKP2 5p13.2 RP11-624K2 - - - - - - - G G G
TRIO 5p15.2 RP11-1150G22 - - - - - - - G G G
hTERT 5p15.33 RP11-117B23 - - - - - - - G G G
GDNF 5p13.2 RP11-914H3 - - - - - - - G G G
ANKH 5p15.2 RP11-99I1 - G - G G G - G G G
TUSC3 8p22 44L18/184C1 - - - L - L L L L -
ZNF-217 20q13.2 RP4-724E16 G - G G G - - - - G
CYP24A1 20q13.2 RP5-1075G21 G - G G G - - - - G
MYBL2 20q13.12 RP11-153L9 G - G G G - - - - G
AIB1 20q12 RP11-1151C1 G - G G G - - - - G
(-) no aberration; G – gain; L – loss. Cell lines: 1 – CSCC1; 7 – CSCC7; 8 – CC8; 10a – CC10A; 10b – CC10b; 11 – CC11-; 11+ – CC11+; S – SiHa, 
C – CaSki, H – HeLa.
Table 4: Genes significantly overexpressed in cell lines with amplification of 5p (T-test, p < 0.05).
Gene symbol Chromosomal Location
ARSB chr5p11
RPL37 chr5p13
SKP2 chr5p13
OSMR chr5p13.1
TARS chr5p13.2
RAD1 chr5p13.2
SUB1 chr5p13.3
RNASEN chr5p13.3
POLS chr5p15
SDHA chr5p15
TRIO chr5p15.1-p14
NDUFS6 chr5p15.33
TRIP13 chr5p15.33
PDCD6 chr5pter-p15.2BMC Genomics 2007, 8:53 http://www.biomedcentral.com/1471-2164/8/53
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LOH at 6p21.3 is demonstrated for microsatellite marker C125 Figure 4
LOH at 6p21.3 is demonstrated for microsatellite marker C125. Tumour samples from which cell lines CC11 and CC10 origi-
nated were analyzed for LOH. In black the particular alleles are depicted and in grey the marker is shown.
FISH of metaphase preparations depicting copy number alterations Figure 3
FISH of metaphase preparations depicting copy number alterations. A) CaSki – 5 chromosomes 5 (centromere 5-blue; TRIO-
green; SKP2-red); one isochromosome 5p (yellow arrow), 2 translocations of RP11-1150G22, encompassing TRIO (green 
arrow) and 2 translocations of RP11-624K2, encompassing SKP2 (red arrow). B) CaSki – 3 chromosomes 8 (centromere 8-
red, TUSC3-green) with loss of one copy the BACs encompassing TUSC3, RP11-44L18/184C1 (green arrow). C) HeLa – 4 
chromosomes 20 (centromere 20-blue, ZNF-217-red, CYP24A1-green); one isochromosome 20q (yellow arrow).BMC Genomics 2007, 8:53 http://www.biomedcentral.com/1471-2164/8/53
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of ZNF-217/CYP24A1 at 20q and increased mRNA expres-
sion [51].
Conclusion
From this study we conclude that copy number data
retrieved from either array CGH or SNP are comparable.
The SNP array provided a reliable copy number as well as
genotype information, which was suitable for the analysis
of complex genetic alterations present in cervical cancer
cell lines. Frequently occurring gains, amplifications and
deletions on chromosome arms 5p, 20q and 8q were ver-
ified by FISH. Amplification at 5p associated with overex-
pression of candidate oncogenes. Accordingly, the
possibility to integrate genome-wide LOH, copy number
and gene expression is useful for the identification of gene
specific targets that could be relevant for the development
and progression in cervical cancer.
Methods
Cell lines, cultures and patient material
Human cervical cancer cell lines, HeLa, SiHa, CaSki
(ATCC, Rockville, MD), CSCC1, CSCC7, CC8, CC10A,
CC10B, CC11-, and CC11+ [52] were maintained in RPMI
1640 (Life Technologies, Grand Island, NY), supple-
mented with 10% fetal calf serum, streptomycin and pen-
icillin at 37°C in a humid atmosphere containing 5%
CO2. CC10A, CC10B, CC11- and CC11+ are sub clones
from the same cell line, CC10 and CC11 respectively. Five
normal primary cervical epithelial cell cultures (NPE)
were prepared as described [53]. Two archival formalin-
fixed, paraffin-embedded cervical carcinomas were
obtained from the tissue bank of the Department of
Pathology (LUMC, Leiden, The Netherlands).
DNA and RNA isolation
DNA from all the cultured cell lines was isolated using the
salting out procedure according to Miller and Polesky
[54]. Total RNA was isolated using TRIzol reagent (Gibco
BRL/Life Technologies, Breda, The Netherlands) from
cells that were grown to approximately 60% confluence in
250 ml culture flasks (Greiner, Frickenhausen, Germany).
Total RNA was cleaned with Rneasy cleanup system col-
umns (Qiagen GmbH, Hilden, Germany).
Array CGH
Array CGH was performed as previously described [55].
Slides containing ~3,500 BACs in triplicate were made at
the Leiden University Medical Centre. The particular BAC
set used (Welcome Trust Sanger Institute (UK)) comprises
clones spaced at ~1 Mb density over the full genome, a set
of subtelomeric sequences for each chromosome arm, and
a few hundred probes selected for their involvement in
oncogenesis. Information regarding the full set is availa-
ble in the "Cytoview" window of the Sanger Center map-
ping database site, Ensembl[56]. The test/reference ratios
were normalized for the median of the ratios of all fea-
tures. The BioConductor package Limma (Smyth and
Speed 2003) version 2.6.0 was used to perform back-
ground correction with method 'Edwards' and within
array normalization with method 'Printtiploess', between
array normalization was not performed. After normaliza-
tion the replicate spots were averaged. Probes with less
than 2 valid replicate values, and probes that showed a
standard deviation above 0.1 between the replicate values
were excluded. Chromosomal regions demonstrating a
ratio of between 1.11 and 1.41 were scored as 'gained' and
a ratio of 1.41 or greater was scored as 'amplified'. Chro-
Box plots show differences in gene expression measured by qRT-PCR of SKP2 (p = 0.003, ANOVA); TRIO (p < 0.001,  ANOVA) and ANKH (p < 0.001, ANOVA) in cell lines with and without amplification of 5p and normal cervical epithelial cell  cultures (NPE) Figure 5
Box plots show differences in gene expression measured by qRT-PCR of SKP2 (p = 0.003, ANOVA); TRIO (p < 0.001, 
ANOVA) and ANKH (p < 0.001, ANOVA) in cell lines with and without amplification of 5p and normal cervical epithelial cell 
cultures (NPE). Ampl: amplification.BMC Genomics 2007, 8:53 http://www.biomedcentral.com/1471-2164/8/53
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mosomal regions showing a ratio of between 0.84 and
0.73 were scored as lost whereas a second threshold for
loss was set for regions showing a ratio of less than 0.73.
SNP 10K array
Affymetrix 10K SNP array (Santa Clara, CA) containing
11,555 biallelic polymorphic sequences randomly distrib-
uted throughout the genome, excluding the Y chromo-
some, was used. The median distance between SNPs is
~105 kb. The average heterozygosity for these SNPs is
0.37, with an average minor allele frequency of 0.25. DNA
samples, including two control DNA samples from
Affymetrix, were assayed according to the manufacturer's
manual protocol (GeneChip Mapping Assay manual).
Genotyping was performed using GDAS (Affymetrix,
Santa Clara, CA) and copy number values were calculated
using dChip version 1.3. Stretches of homozygous SNPs
equal or longer than 24 calls were defined as LOH.
Gene expression microarray
Affymetrix focus arrays (Santa Clara, CA), representing
8,793 human sequences from the NCBI Refseq database,
were used for mRNA expression profiling according to the
manufacturer's instructions. Data files of all microarrays
were normalized using the Robust Multi-Chip Average
(GCRMA) method [57]. Quality control was performed
on the arrays using Affy-Probe Level Model (AffyPLM)
[58]. Microarrays for each cell line were performed in
duplicate. The signal intensities of the replicates were
averaged after normalization. To identify differentially
expressed genes between cell lines with and without gain,
amplification or deletion of a chromosome arm or region,
unpaired two-sample t-tests were performed.
Integrative analysis
To compare the data from the 3 high dimensional tech-
niques; array CGH, SNP array, and expression array, the
copy number and expression values were transformed to
contain log 2, median centered values. Access to complete
microarray data sets will be available at NCBI Gene
Expression Omnibus. Normalization of array CGH data
and expression arrays resulted in values that are equiva-
lent to log2 intensity values. The data retrieved from
dChip version 1.3 from the SNP arrays showed a copy
number of 2 for unaffected probes on a linear scale. These
data were divided by 2 and log2 transformed. A per gene
median centering to zero was performed. Array CGH
smoothing was performed using a smoother that retains
sharp transitions between regions with genomic altera-
tions. The correlation between gene expression and phys-
ical genomic alterations was determined by computing
the Pearson correlation between the expression of each
gene to the smoothed array CGH value of the nearest BAC
on the chromosome. The resulting p-values were sub-
jected to the Benjamini and Yekutieli false discovery rate
procedure [59]. The data retrieved from dChip version 1.3
from the SNP arrays showed a copy number of 2 for unaf-
fected probes on a linear scale.
Fluorescent in situ hybridization (FISH)
Metaphase preparations of all cell lines were obtained
using colcemid according to standard procedures [60].
BAC probes for the genes selected on chromosome 5,
chromosome 8 and chromosome 20 (Table 5) were
ordered from the BACPAC Resource Centre at Children's
Hospital Oakland Research Institute (Oakland, CA). All
BAC probes were fluorescein-12-dUTP- or digoxigenin-
12-dUTP-labelled (Roche, Basel, Switzerland). The fol-
lowing centromere probes were used: the pG-A16 probe
for centromere 5; the D8Z2 probe for centromere 8; and
the p3.4 probe for chromosome 20. All centromere
probes were kindly provided by J. Wiegant (Department
of Molecular and Cellular Biology, LUMC) and labelled
with biotin-16-dUTP (Roche, Basel, Switzerland). Triple-
colour FISH experiments were performed as previously
described [61]. Centromere and BAC signals of 20 met-
aphases were analyzed per probe combination per cell
line.
Microsatellite analysis
Genomic DNA was isolated from flow-sorted tumour cell
subpopulations derived from formalin-fixed, paraffin-
embedded cervical carcinomas as previously described
[62]. Eight fluorescein-labelled primer pairs of microsatel-
lite markers comprising MOGC, D6S265, C125, TY2A,
TNFα, D6S273, D6S294 and D6S1666 [63], spanning
altogether 26 MB from 6p22.1 to 6p12.1, were used. PCR,
electrophoresis and analysis was performed as described
previously [64]. Comparing normal and tumour DNA, a
reduction of more than 50% of one allele was assigned as
complete LOH.
Quantitative real-time PCR (qRT-PCR)
qRT-PCR was performed as described previously [65].
Expression of the genes of interest was normalized by geo-
metric averaging of multiple internal control genes
(CPSF6, HNRPM, EEF1A1, RPL11 and RPL13) using the
Genorm program [66]. Out of 5 normalization genes the
best 3 were selected using this program; EEF1A1, RPL13
and RPL11. Primer sequences for RPL11 are 5'-ACTTCG-
CATCCGCAAACTCT (FWD) and 5'-AAGGTGTTGGAG-
CAGXTCACA (REV). Primer sequences for EEF1A1,
RPL13 were reported previously [65]. Commercially avail-
able primers were used for TUSC3, ANKH and TRIO
(Superarray, Frederick, USA). Primer sequences for SKP2
are: 5'-CCTATCACTCAGTCGGTGCTATGA (FWD) and 5'-
AATCGTGCCAGATGGTACCCT (REV). To determine dif-
ferential gene expression between normal cervical epithe-
lial cell cultures (NPE), cell lines with and withoutBMC Genomics 2007, 8:53 http://www.biomedcentral.com/1471-2164/8/53
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deletion, gain or amplification, one-way ANOVA was per-
formed.
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